You are here

Article info

Article menu
XML
Respiratory infection
Rationale for azithromycin in COVID-19: an overview of existing evidence

Authors

  • Iwein Gyselinck Respiratory Diseases, KU Leuven University Hospitals, Leuven, Flanders, BelgiumDepartment CHROMETA - Research group BREATHE, KU Leuven, Leuven, Flanders, Belgium PubMed articlesGoogle scholar articles
  • Wim Janssens Respiratory Diseases, KU Leuven University Hospitals, Leuven, Flanders, BelgiumDepartment CHROMETA - Research group BREATHE, KU Leuven, Leuven, Flanders, Belgium PubMed articlesGoogle scholar articles
  • Peter Verhamme Cardiovascular Diseases, KU Leuven University Hospitals, Leuven, Flanders, BelgiumCentre for Molecular and Vascular Biology, KU Leuven, Leuven, Flanders, Belgium PubMed articlesGoogle scholar articles
  • Robin Vos Respiratory Diseases, KU Leuven University Hospitals, Leuven, Flanders, BelgiumDepartment CHROMETA - Research group BREATHE, KU Leuven, Leuven, Flanders, Belgium PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Iwein Gyselinck; iwein.gyselinck{at}kuleuven.be
View Full Text

Citation

Gyselinck I, Janssens W, Verhamme P, et al
Rationale for azithromycin in COVID-19: an overview of existing evidence
BMJ Open Respiratory Research 2021;8:e000806. doi: 10.1136/bmjresp-2020-000806

Publication history

  • Received October 20, 2020
  • Revised November 27, 2020
  • Accepted November 30, 2020
  • First published January 13, 2021.
Online issue publication 
July 13, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.